Y Zhao1, G Qiao1, X Wang1, Y Song1, X Zhou1, N Jiang1, L Zhou1, H Huang1, J Zhao1, M A Morse2,3, A Hobeika3, J Ren4,5, H K Lyerly6. 1. Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, 10 Tieyi Rd, Beijing, 100038, China. 2. Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. 3. Department of Surgery, Duke University Medical Center, 571 Research Drive, Suite 433, Box 2606, Durham, NC, 27710, USA. 4. Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, 10 Tieyi Rd, Beijing, 100038, China. jun.ren@duke.edu. 5. Department of Surgery, Duke University Medical Center, 571 Research Drive, Suite 433, Box 2606, Durham, NC, 27710, USA. jun.ren@duke.edu. 6. Department of Surgery, Duke University Medical Center, 571 Research Drive, Suite 433, Box 2606, Durham, NC, 27710, USA. kim.lyerly@duke.edu.
Abstract
BACKGROUND: Advanced non-small cell lung cancer (NSCLC) has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells (DC-CIK) administered with chemotherapy (CT) in this malignancy. METHODS: We have developed a new clinical trial design termed as the prospective patient's preference-based study (PPPS). Consecutive patients (n = 135) with advanced NSCLC were treated with DC-CIK administered with CT or mono-therapy (CT or DC-CIK alone). RESULTS: For all the patients, the median PFS was 5.7 months and the median OS was 17.5 months. The 1-year PFS and OS rates were 29.4% and 58.2%, respectively. The 1-year PFS and OS rates for DC-CIK plus CT were significantly higher than that in the group of patients who received DC-CIK alone and CT alone (P < 0.05). The number of adoptively infused DC-CIK cells was associated with clinical efficacy. After adjusting for competing risk factors, DC-CIK combined with CT and infused number of CIKs remained independent predictors of PFS and OS. Phenotypic analysis of peripheral blood mononuclear cells showed that CD8+CD28+, and CD8+CD28- T cells, changed significantly in all groups (P < 0.01). The CD3+ T cells increased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01), while CD3-CD16+CD56 T cells decreased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01). CONCLUSIONS: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.
BACKGROUND: Advanced non-small cell lung cancer (NSCLC) has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells (DC-CIK) administered with chemotherapy (CT) in this malignancy. METHODS: We have developed a new clinical trial design termed as the prospective patient's preference-based study (PPPS). Consecutive patients (n = 135) with advanced NSCLC were treated with DC-CIK administered with CT or mono-therapy (CT or DC-CIK alone). RESULTS: For all the patients, the median PFS was 5.7 months and the median OS was 17.5 months. The 1-year PFS and OS rates were 29.4% and 58.2%, respectively. The 1-year PFS and OS rates for DC-CIK plus CT were significantly higher than that in the group of patients who received DC-CIK alone and CT alone (P < 0.05). The number of adoptively infused DC-CIK cells was associated with clinical efficacy. After adjusting for competing risk factors, DC-CIK combined with CT and infused number of CIKs remained independent predictors of PFS and OS. Phenotypic analysis of peripheral blood mononuclear cells showed that CD8+CD28+, and CD8+CD28- T cells, changed significantly in all groups (P < 0.01). The CD3+ T cells increased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01), while CD3-CD16+CD56 T cells decreased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01). CONCLUSIONS: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.
Authors: Brian G Till; Michael C Jensen; Jinjuan Wang; Eric Y Chen; Brent L Wood; Harvey A Greisman; Xiaojun Qian; Scott E James; Andrew Raubitschek; Stephen J Forman; Ajay K Gopal; John M Pagel; Catherine G Lindgren; Philip D Greenberg; Stanley R Riddell; Oliver W Press Journal: Blood Date: 2008-05-28 Impact factor: 22.113
Authors: Shuo Wang; Yuguang Song; Michael A Morse; Pingping Sun; Guoliang Qiao; Xiaoli Wang; Xinna Zhou; Amy Hobeika; Jun Ren; Herbert Kim Lyerly Journal: Am J Cancer Res Date: 2020-12-01 Impact factor: 6.166
Authors: Iris A E van der Hoorn; Georgina Flórez-Grau; Michel M van den Heuvel; I Jolanda M de Vries; Berber Piet Journal: Front Immunol Date: 2021-06-28 Impact factor: 7.561
Authors: Lefu Huang; Guoliang Qiao; Michael A Morse; Xiaoli Wang; Xinna Zhou; Jiangping Wu; Amy Hobeika; Jun Ren; Herbert K Lyerly Journal: Oncol Lett Date: 2019-10-04 Impact factor: 2.967